Nektar Rezpegaldesleukin Shows 52-Week Alopecia Results
SAN FRANCISCO, April 20, 2026 Nektar Therapeutics has reported compelling 52-week topline results from the Phase 2b REZOLVE-AA trial,...
alopecia areata
Advertisement
Rezpegaldesleukin Shows Strong Phase 2b Results in AD
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
Nektar Therapeutics Reports Phase 2b Rezpegaldesleukin Data
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
Legacy Advances Cinainu into Phase 3 Alopecia Areata Trial
LAUSANNE, Switzerland | January 6, 2026 — Legacy Healthcare announced that it will advance its topical botanical drug candidate,...
Advertisement
